NCT04209855 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 226
- group Id
- BG002
- value
- 453
- units
- Participants
- groups
- description
- Participants received single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.
- id
- BG000
- title
- Mirvetuximab Soravtansine
- description
- Participants received a dose of IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.
- id
- BG001
- title
- Investigator's Choice (IC) Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.85
- value
- 63.3
- group Id
- BG001
- spread
- 9.30
- value
- 62.3
- group Id
- BG002
- spread
- 9.58
- value
- 62.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 226
- group Id
- BG002
- value
- 453
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 27
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 340
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 86
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 53
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 145
- group Id
- BG002
- value
- 301
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 86
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The intent-to-treat (ITT) population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 226
- group Id
- BG002
- value
- 453
- units
- Participants
- groups
- description
- Participants received single-agent MIRV at 6 mg/kg AIBW administered IV on Day 1 of Q3W.
- id
- BG000
- title
- Mirvetuximab Soravtansine
- description
- Participants received a dose of IC chemotherapeutic agent calculated using BSA. Paclitaxel administered at 80 mg/m\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan administered at 4 mg/m\^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could have been administered at 1.25 mg/m\^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin administered at 40 mg/m\^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could have been administered as a 1-hour infusion.
- id
- BG001
- title
- Investigator's Choice (IC) Chemotherapy
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 9.85
- value
- 63.3
- group Id
- BG001
- spread
- 9.30
- value
- 62.3
- group Id
- BG002
- spread
- 9.58
- value
- 62.8
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 226
- group Id
- BG002
- value
- 453
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 27
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 177
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 340
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 48
- group Id
- BG002
- value
- 86
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 25
- group Id
- BG002
- value
- 53
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 145
- group Id
- BG002
- value
- 301
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 35
- group Id
- BG001
- value
- 51
- group Id
- BG002
- value
- 86
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- The intent-to-treat (ITT) population included all participants randomized to the study, regardless of whether or not participants received study treatment (MIRV or IC Chemo).
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle